GB2430622A - Combination of methylxanthine compounds and steroids to treat chronic respiratory diseases - Google Patents

Combination of methylxanthine compounds and steroids to treat chronic respiratory diseases

Info

Publication number
GB2430622A
GB2430622A GB0620830A GB0620830A GB2430622A GB 2430622 A GB2430622 A GB 2430622A GB 0620830 A GB0620830 A GB 0620830A GB 0620830 A GB0620830 A GB 0620830A GB 2430622 A GB2430622 A GB 2430622A
Authority
GB
United Kingdom
Prior art keywords
combination
steroids
respiratory diseases
treat chronic
chronic respiratory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB0620830A
Other versions
GB2430622B (en
GB0620830D0 (en
Inventor
Justian Craig Fox
Mary Frances Fitzgerald
Harry Finch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Argenta Discovery Ltd
Original Assignee
Argenta Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0502949A external-priority patent/GB0502949D0/en
Priority claimed from GB0526124A external-priority patent/GB0526124D0/en
Application filed by Argenta Discovery Ltd filed Critical Argenta Discovery Ltd
Priority to GB0716700A priority Critical patent/GB2442828A/en
Priority claimed from PCT/GB2006/000482 external-priority patent/WO2006085102A1/en
Publication of GB0620830D0 publication Critical patent/GB0620830D0/en
Publication of GB2430622A publication Critical patent/GB2430622A/en
Application granted granted Critical
Publication of GB2430622B publication Critical patent/GB2430622B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

There is provided the use of a methylxanthine derivative such as theophylline and a steroid in a synergistic combination for the treatment of chronic obstructive pulmonary disease, wherein the combination is administered by the inhaled route for pulmonary delivery.
GB0620830A 2005-02-11 2006-02-13 Inhaled combination therapy Expired - Fee Related GB2430622B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB0716700A GB2442828A (en) 2005-02-11 2006-02-13 Combination of a methylxanthine compound and a steroid to treat chronic respiratory disease

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0502949A GB0502949D0 (en) 2005-02-11 2005-02-11 Combination therapy
GB0526124A GB0526124D0 (en) 2005-12-22 2005-12-22 Inhaled combination therapy
PCT/GB2006/000482 WO2006085102A1 (en) 2005-02-11 2006-02-13 Combination of methylxanthine compounds and steroids to treat chronic respiratory diseases

Publications (3)

Publication Number Publication Date
GB0620830D0 GB0620830D0 (en) 2006-12-13
GB2430622A true GB2430622A (en) 2007-04-04
GB2430622B GB2430622B (en) 2008-03-05

Family

ID=37547091

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0620830A Expired - Fee Related GB2430622B (en) 2005-02-11 2006-02-13 Inhaled combination therapy

Country Status (1)

Country Link
GB (1) GB2430622B (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0421587A2 (en) * 1989-08-10 1991-04-10 Beecham Group p.l.c. Xanthine derivatives used in asthma
WO2006013359A1 (en) * 2004-08-05 2006-02-09 Argenta Discovery Limited Medicaments for treating chronic respiratory disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0421587A2 (en) * 1989-08-10 1991-04-10 Beecham Group p.l.c. Xanthine derivatives used in asthma
WO2006013359A1 (en) * 2004-08-05 2006-02-09 Argenta Discovery Limited Medicaments for treating chronic respiratory disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Evans D J et al "A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma" The New England Journal of Medicine, vol 337 no.20, 1997, pages 1412-1418 *
Morali T et al "Efficacy of Inhaled Budesonide and oral theophylline in asthmatic subjects" vol 38(8) page 673-679, 2001 *
Rivington R N et al "Efficacy of Uniphyl, Salbutamol, and their combination in asthmatic patients on high-dose inhaled steroids" American Journal of Respiratory and Critical Care vol. 151 1995 pages 325-332 *

Also Published As

Publication number Publication date
GB2430622B (en) 2008-03-05
GB0620830D0 (en) 2006-12-13

Similar Documents

Publication Publication Date Title
IL183696A0 (en) Combination of methylxanthine compounds and steroids to treat chronic respiratory diseases
WO2012047674A3 (en) Methods and compositions for disease treatment using inhalation
NO20070597L (en) Medication centers to treat chronic respiratory disease.
UY26959A1 (en) NEW INHALATION POWDERS CONTAINING TIOTROPY
UA98136C2 (en) Use of aclidinium for the treatment of respiratory diseases
SG169233A1 (en) Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
MX2019006938A (en) Methods and compositions for treatment of pulmonary hypertension and other lung disorders.
NZ587561A (en) Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations (an muscarinic antagnoist)
WO2007109118A3 (en) RECOMBINANT HUMAN CC 10 (rhCC10) FOR TREATMENT OF RESPIRATORY DISORDERS
ECSP055855A (en) INHALATION POWDER DRUGS CONTAINING A TIOTROPIO SALT AND SALMETEROLXINAFOATO
HK1104471A1 (en) Opioids for the treatment of the chronic obstructive pulmonary disease (copd)
WO2007136518A3 (en) Treatment of autoimmune disorders
NO20054767L (en) Compositions comprising apomorphine for lung inhalation
UA92584C2 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
WO2008022189A3 (en) Administration of high potency platinum compound formulations by inhalation
UA101652C2 (en) Composition for inhalation comprising aclidinium for the treatment of asthma and chronic obstructive pulmonary disease
WO2003105775A3 (en) Dihydrate dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compostions thereof
BR112014029735A2 (en) dosage form and formulation of abediterol
EA201201393A1 (en) INHALER, DEVELOPED FOR DELIVERY OF MEDICINES AS DRY POWDER
GB2430622A (en) Combination of methylxanthine compounds and steroids to treat chronic respiratory diseases
UY28096A1 (en) NEW PULVEURLENT FORMULATION CONTAINING INHALATION TIOTROPY
WO2007046113A3 (en) Novel pharmaceutical composition comprising alkaloid and process thereof
WO2009062193A3 (en) Methods for administering corticosteroid formulations
WO2007066151A3 (en) Topical compositions for treatment of respiratory disorders
MX2008010757A (en) Combinations of steroids and methylxanthine compounds.

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20100213

S73 Revocation on comptroller's initiative (section 73/patents act 1977)

Free format text: PATENT REVOKED; PATENT REVOKED UNDER SECTION 73(2) ON 1 NOVEMBER 2010